Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 6/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.46 |
| ▸ | MMP13 | P45452 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998583 | 0.91 | PDE10A (0.46) | CACNA1GCACNA1HCACNA1IMMP13MAPK1 | |
| SCHEMBL4255358 | 0.87 | MMP13 (0.47) | CACNA1GCACNA1HCACNA1IMMP13MAOB | |
| SCHEMBL10165651 | 0.86 | MMP13 (0.46) | CACNA1GCACNA1HCACNA1IMMP13MAPK1 | |
| SCHEMBL14124308 | 0.86 | CACNA1G (0.46) | CACNA1GCACNA1HCACNA1IMMP13MAPK1 | |
| SCHEMBL4260178 | 0.85 | CACNA1G (0.45) | CACNA1GCACNA1HCACNA1IMMP13MAPK1 | |
| SCHEMBL4224949 | 0.85 | MMP13 (0.48) | CACNA1GCACNA1HCACNA1IMMP13MAPK1 | |
| SCHEMBL8184004 | 0.85 | CACNA1G (0.45) | CACNA1GCACNA1HCACNA1IMMP13MAOB | |
| SCHEMBL4258247 | 0.84 | CACNA1G (0.50) | CACNA1GCACNA1HCACNA1IMMP13MAPK1 | |
| SCHEMBL4229010 | 0.84 | CACNA1G (0.45) | CACNA1GCACNA1HCACNA1IMMP13MAPK1 | |
| SCHEMBL4260309 | 0.83 | CACNA1G (0.43) | CACNA1GCACNA1HCACNA1IMMP13MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102211-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | CACNA1G 1476/4885CACNA1H 1429/4885CACNA1I 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.